| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Trevi Therapeutics, Inc.'s insiders have reduced their positions by a net 39,473 shares worth roughly $596K.
Classified under Biotechnology (Health Care sector), TRVI's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 26.1K | $13.3K | - | |
| Dir | 6.4K | $100.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Heffernan Michael Thomas | Director | Sale+OE10b5-1 | 39,473 | $15.09 | $595,805.57 | -86.1% | - | - | |
| Mar 25, 2025 | Sciascia Thomas | Chief Scientific Officer | Sale+OE | 2,631 | $6.60 | $17,364.60 | -1.2% | -13.0% | +73.1% | |
| Mar 21, 2025 | Good Jennifer L | President &CEO | Sale+OE | 5,263 | $6.58 | $34,624.75 | -2.4% | -7.9% | +64.0% | |
| Mar 10, 2025 | Simon Farrell | Chief Commercial Officer | Sale+OE10b5-1 | 81,313 | $6.75 | $548,877.91 | -51.4% | +5.6% | +93.7% | |
| Sep 9, 2024 | Good Jennifer L | President &CEO | Sale+OE | 6,059 | $3.03 | $18,371.02 | -2.8% | -14.7% | +169.9% | |
| Sep 5, 2024 | Good Jennifer L | President &CEO | Sale+OE | 55,121 | $3.09 | $170,192.71 | -20.5% | -16.1% | +126.1% | |
| Aug 27, 2024 | Meeker David P | Director | Sale+OE | 4,555 | $2.93 | $13,352.53 | -1.3% | +0.3% | +174.9% | |
| Aug 19, 2024 | Sciascia Thomas | Chief Scientific Officer | Sale+OE | 16,496 | $2.96 | $48,882.60 | -7.0% | -5.1% | +146.5% | |
| Aug 16, 2024 | Sciascia Thomas | Chief Scientific Officer | Sale+OE | 31,505 | $2.77 | $87,227.69 | -12.5% | +3.2% | +171.5% | |
| May 29, 2024 | Sciascia Thomas | Chief Scientific Officer | Sale+OE | 53,368 | $2.55 | $136,109.75 | -19.9% | +14.6% | +150.4% |